greeksoup/ stock research
Stock research / United States / BMY · Pharmaceutical Preparations · NYSE

Bristol-Myers Squibb Co. (BMY)

Bristol Myers Squibb discovers, develops, licenses, manufactures, markets, distributes and sells medicines, and operates in a single segment. It was incorporated in Delaware in August 1933 as Bristol-Myers Company, successor to a New York business started in 1887, and took its present name in 1989 following a merger. Its therapeutic focus is oncology, hematology, immunology, cardiovascular and neuroscience. Products are sold worldwide, principally to wholesalers, distributors and specialty pharmacies and to a lesser extent to retailers, hospitals, clinics, government agencies and directly to patients. Manufacturing operations sit in the United States, Puerto Rico, the Netherlands, Ireland and Switzerland. The United States was 69% of revenues in 2025 and international markets 29%.

Bristol-Myers Squibb Co.

Bristol Myers Squibb discovers, develops, licenses, manufactures, markets, distributes and sells medicines, and operates in a single segment. It was incorporated in Delaware in August 1933 as Bristol-Myers Company, successor to a New York business started in 1887, and took its present name in 1989 following a merger. Its therapeutic focus is oncology, hematology, immunology, cardiovascular and neuroscience. Products are sold worldwide, principally to wholesalers, distributors and specialty pharmacies and to a lesser extent to retailers, hospitals, clinics, government agencies and directly to patients. Manufacturing operations sit in the United States, Puerto Rico, the Netherlands, Ireland and Switzerland. The United States was 69% of revenues in 2025 and international markets 29%.

The company splits its medicines into a Growth Portfolio and a Legacy Portfolio. The split matters because most of a branded medicine's commercial value is usually realised while it still has market exclusivity, and the filing states that when those rights expire and generic versions are approved and marketed there are often substantial and rapid declines in the sales of the original product.

The Growth Portfolio

Opdivo, nivolumab, is a fully human monoclonal antibody binding to PD-1 on T and NKT cells, approved across bladder, blood, colorectal, head and neck, kidney, liver, lung, melanoma, mesothelioma, stomach and esophageal cancers. Opdivo Qvantig is the subcutaneous form, covering most previously approved adult solid tumour indications, and is sold as Opdivo SC in the European Union. Yervoy, ipilimumab, is a CTLA4 immune checkpoint inhibitor for unresectable or metastatic melanoma, and the Opdivo plus Yervoy regimen is approved in multiple markets across lung, melanoma, mesothelioma, kidney, colorectal, liver and esophageal cancers. Opdualag combines nivolumab with relatlimab, a LAG-3 blocking antibody, for unresectable or metastatic melanoma in patients aged 12 and over.

Two cell therapies sit alongside them. Breyanzi is a CD19-directed genetically modified autologous CAR-T cell therapy for several relapsed or refractory lymphomas and leukemias, and Abecma is a BCMA genetically modified autologous CAR-T cell therapy for relapsed or refractory multiple myeloma after two or more prior lines of therapy. Reblozyl is an erythroid maturation agent for anemia in beta thalassemia and in lower-risk myelodysplastic syndromes. Orencia, abatacept, is a fusion protein for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis, and for preventing acute graft versus host disease.

The rest of the growth portfolio is oral. Sotyktu is a selective allosteric tyrosine kinase 2 inhibitor for moderate-to-severe plaque psoriasis. Zeposia is an immunomodulatory drug for relapsing forms of multiple sclerosis and for moderately to severely active ulcerative colitis. Camzyos is a cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy. Krazati is a small-molecule inhibitor of the KRASG12C mutation, used in lung cancer after prior therapy and, with cetuximab, in colorectal cancer. Cobenfy combines xanomeline, a muscarinic agonist, with trospium chloride, a peripheral muscarinic antagonist, for schizophrenia in adults.

The Legacy Portfolio

Eliquis, apixaban, is an oral Factor Xa inhibitor used to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation and to treat deep vein thrombosis and pulmonary embolism. Revlimid, lenalidomide, is an oral immunomodulatory drug used with dexamethasone in multiple myeloma, as maintenance after autologous stem cell transplant, and across several other blood cancers. Pomalyst, sold as Imnovid outside the United States, is for multiple myeloma patients who have already had at least two prior therapies. Sprycel is an oral inhibitor of multiple tyrosine kinases for Philadelphia chromosome-positive chronic myeloid leukemia in adults and in children from the age of one. Abraxane is a solvent-free protein-bound chemotherapy combining paclitaxel with albumin on the company's own Nab technology, used in breast, lung and pancreatic cancer.

How exclusivity works, and who it competes with

Market exclusivity comes from two things. Patents give the originator the right to exclude others from practising an invention, and can cover the active ingredient, uses of the product, formulations, delivery mechanisms and manufacturing processes, running for different periods in different countries. Regulatory exclusivity is separate: a period after approval during which the regulator may not rely on the originator's own data to approve a generic or biosimilar copy, which can extend protection beyond the patent term. The company competes with other global research-based drug companies, with many smaller research companies of narrower therapeutic focus, and with generic drug manufacturers.

From Bristol Myers Squibb's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Bristol-Myers Squibb became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 29 October 2026
Revenue
$13.1 billion
+6.9% on the year · +0.7% on the quarter
Q4 FY2024Q3 FY2026
Net income
$2.2 billion
-1.8% on the year · -34.8% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$1.05
-2.8% on the year · -35.2% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 11 February 2026
Revenue
$48.2 billion
-0.2% on the year
FY2018FY2025
Net income
$7.1 billion
FY2018FY2025
Diluted EPS
$3.46
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsBristol-Myers Squibb (BMY) reported revenue of $48.2 billion for fiscal 2025, the year ended 31 December 2025, down 0.2% on the year before. Net income was $7.1 billion and diluted earnings per share $3.46. Revenue was $48.3 billion in fiscal 2024, $45.0 billion in fiscal 2023, $46.2 billion in fiscal 2022 and $46.4 billion in fiscal 2021. Net income in the same years was a loss of $8.9 billion, $8.0 billion, $6.3 billion and $7.0 billion. Over the twelve months to 30 September 2026, Bristol-Myers Squibb reported revenue of $50.0 billion and net income of $9.2 billion. Revenue grew 2.5% a year, compounded, over the five years to fiscal 2025. Bristol-Myers Squibb declared $2.52 a share in dividends over the last four quarters and had 2.04 billion shares outstanding at the latest filed count. At 30 September 2026 it carried $42.9 billion of debt and $9.6 billion of cash. At the close of 6 November 2026 the market cap of Bristol-Myers Squibb was $127.0 billion, 13.8 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE39.5%
ROCE17.1%
Operating margin22.6%
Net margin18.5%
FCF margin18.6%
Interest cover6.8x
Debt to equity1.83x
Cash conversion1.15x
Share count, last 12 months0.4%
Sales CAGR, 3 years1.4%
Profit CAGR, 3 years3.7%
EPS, TTM$4.51

At the close of 6 November 2026

Price$62.14
Market cap$127.0 billion
Stock P/E13.8x
Price to book5.4x
EV / EBITDA11.3x
Dividend yield4.1%
Market cap / sales2.5x
52-week high$68.09
52-week low$45.79
Price, 1 year33.3%
Price CAGR, 3 years5.9%
Price CAGR, 5 years0.9%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of Bristol-Myers Squibb Co.'s balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.
BMYgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue11,98511,64811,88711,21811,40611,33711,22610,96611,47711,86512,20111,89212,34211,20112,26912,22212,50211,48912,97313,069
Cost of revenue2,3562,4712,7202,3532,5932,5662,8762,5062,7452,9323,2672,9574,8123,0333,3723,4354,0963,4213,7264,146
Gross profit9,6299,1779,1678,8658,8138,7718,3508,4608,7328,9338,9348,9357,5308,1688,8978,7878,4068,0689,2478,923
Gross margin80%79%77%79%77%77%74%77%76%75%73%75%61%73%73%72%67%70%71%68%
R&D2,6072,2602,3212,4182,5102,3212,2582,2422,4782,6952,8992,3743,1912,2572,5802,5282,5862,6492,9592,365
SG&A2,3541,8311,7871,9302,2661,7621,9342,0032,0732,3671,9281,9832,1361,5841,7131,7892,1811,6171,8261,699
Operating income1,8581,6871,9582,2091,8592,7701,8592,1371,674-11,5161,2861,6761752,9711,7733,1141,4703,2394,0862,536
Operating margin16%14%16%20%16%24%17%19%15%-97%11%14%1%27%14%25%12%28%31%19%
Interest expense323326313299294288282280316425521505496494485480432411407403
Pre-tax income1,8581,6871,9582,2091,8592,7701,8592,1371,674-11,5161,2861,6761752,9711,7733,1141,4703,2404,0862,536
Tax rate-28%24%27%27%-9%18%-12%9%-5%n/a-31%28%57%17%26%30%26%17%19%15%
Net income2,3721,2781,4211,6062,0222,2622,0731,9281,762-11,9111,6801,21172.02,4561,3102,2011,0872,6773,3172,162
Net margin20%11%12%14%18%20%18%18%15%-100%14%10%1%22%11%18%9%23%26%17%
Diluted EPS$1.07$0.59$0.66$0.75$0.95$1.07$0.99$0.93$0.87-$5.89$0.83$0.60$0.04$1.20$0.64$1.08$0.53$1.31$1.62$1.05
Operating cash flow4,0573,8122,2613,6873,3062,9701,8874,7514,2522,8342,3265,5914,4391,9543,9176,3111,9741,1043,3934,181
Capital expenditure320253272247346278259342330284262324378260361320370347305344
Free cash flow3,7373,5591,9893,4402,9602,6921,6284,4093,9222,5502,0645,2674,0611,6943,5565,9911,6047573,0883,837
Buybacks2,7515,0000.07012,3002509054,0000.00.00.00.00.0n/an/an/an/an/an/an/a
Dividends paid1,0991,1851,1501,1541,1451,1961,1971,1911,1601,2121,2171,2161,2181,2581,2621,2631,2621,2831,2871,287
Shares outstanding2,180m2,129m2,135m2,126m2,099m2,101m2,089m2,035m2,022m2,027m2,027m2,028m2,029m2,035m2,035m2,036m2,036m2,042m2,043m2,044m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008FY2009FY2010 †FY2011FY2012FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Revenue15,61717,71518,80819,48421,24417,62116,38515,87916,56019,42720,77622,56126,14542,51846,38546,15945,00648,30048,19450,033
Cost of revenue4,9195,3165,1405,2775,5984,6104,6193,9323,9094,9696,0146,4678,07811,7739,94010,13710,69313,96813,93615,389
Gross profit10,69812,39913,66814,20715,64613,01111,76611,94712,65114,48114,71016,09418,06730,74536,44536,02234,31334,33234,25834,644
Gross margin68.5%70.0%72.7%72.9%73.6%73.8%71.8%75.2%76.4%74.5%70.8%71.3%69.1%72.3%78.6%78.0%76.2%71.1%71.1%69.2%
Research and development3,1603,5123,6473,5663,8393,9043,7314,5345,9205,0126,4686,3326,14810,04810,1959,5099,29911,1599,95110,559
Selling, general and administrative3,9414,1403,9463,6864,2034,2204,9394,8224,8414,9794,7514,5514,8717,6617,6907,8147,7728,4147,2677,323
Operating income2,5234,7765,6026,0716,9812,3402,8912,3812,0775,9155,1315,9684,975-6,8718,0987,7138,440-8,3799,32811,331
Operating margin16.2%27.0%29.8%31.2%32.9%13.3%17.6%15.0%12.5%30.4%24.7%26.5%19.0%-16.2%17.5%16.7%18.8%-17.3%19.4%22.6%
Interest expensen/a3101841451451821992031841671961836561,4201,3341,2321,1661,9471,8911,653
Pre-tax income2,5234,7765,6026,0716,9812,3402,8912,3812,0775,9155,1315,9684,975-6,8718,0987,7138,440-8,3799,32811,332
Income tax4711,0901,1821,5581,721-1613113524461,4084,1561,0211,5152,1241,0841,3684005542,2722,089
Effective tax rate18.7%22.8%21.1%25.7%24.7%-6.9%10.8%14.8%21.5%23.8%81.0%17.1%30.5%n/a13.4%17.7%4.7%n/a24.4%18.4%
Net income2,1655,24710,6123,1023,7091,9602,5632,0041,5654,4571,0074,9203,439-9,0156,9946,3278,025-8,9487,0549,243
Net margin13.9%29.6%56.4%15.9%17.5%11.1%15.6%12.6%9.5%22.9%4.8%21.8%13.2%-21.2%15.1%13.7%17.8%-18.5%14.6%18.5%
Diluted EPS$1.09$2.62$5.34$1.79$2.16$1.16$1.54$1.20$0.93$2.65$0.61$3.01$2.01-$3.99$3.12$2.95$3.86-$4.41$3.46$4.51
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by region FY2009 to FY2025

FY2009FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United States11,86712,80014,03910,3848,3187,7168,18810,72011,35812,58615,34226,57729,21431,50031,21034,10533,27969.1%
Internationaln/an/an/an/an/an/an/a4,2154,9885,6586,26615,31016,31913,82513,09713,19913,82828.7%
Other198112893278421,1127395285535845246318528346999961,0872.3%
Emerging Markets753n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Europe3,6253,6723,8793,7063,9303,5923,491n/an/an/an/an/an/an/an/an/an/an/a
Japan, Asia Pacific, and Canada1,522n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Latin America, Middle East And Africa843n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Rest of Worldn/a2,9003,2373,2043,2953,4594,1423,9643,8773,7334,013n/an/an/an/an/an/an/a
United StatesInternational FY2016 to FY2025OtherRest of World FY2010 to FY2019Europe FY2009 to FY2015Japan, Asia Pacific, and Canada FY2009Latin America, Middle East And Africa FY2009Emerging Markets FY2009
19.5FY201016.4FY201319.4FY201626.1FY201946.2FY202248.2FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2007FY2008FY2009FY2010 †FY2011FY2012FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Operating cash flow3,1533,7074,0654,4914,8406,9413,5453,1482,1053,0585,2757,0668,21014,05216,20713,06613,86015,19014,15610,652
Capital expenditure8439417304243675485375268201,2151,0559518367539731,1181,2091,2481,3111,366
Free cash flow2,3102,7663,3354,0674,4736,3933,0082,6221,2851,8434,2206,1157,37413,29915,23411,94812,65113,94212,8459,286
Free cash flow margin14.8%15.6%17.7%20.9%21.1%36.3%18.4%16.5%7.8%9.5%20.3%27.1%28.2%31.3%32.8%25.9%28.1%28.9%26.7%18.6%
Cash from investing-2025,079-4,380-3,812-1,437-6,727-5721,216-1,5721,480-66.0-2,000-9,913-10,859-538-1,062-2,295-21,352-4,132-5,307
Cash from financing-3,213-2,582-17.0-3,343-2,657-4,333-1,068-2,437-3,624-2,653-4,077-3,5357,621-1,151-16,224-16,962-9,4165,127-10,348-11,441
Depreciation and amortisationn/an/a2996076286817634673763827896371,74610,38010,68610,2769,7609,6004,0112,790
Share-based compensation133181183193161154191213235205199221441779583457518507553551
Buybacksn/an/an/a5761,2212,403433n/an/a2312,4693207,3001,5466,2878,0015,1550.00.0n/a
Dividends paid2,2132,4612,4832,2022,2542,2862,3092,3982,4772,5472,5772,6132,6794,0754,3964,6344,7444,8635,0455,119
Dividend per share$1.15$1.24$1.25$1.29$1.33$1.37$1.41$1.45$1.49$1.53$1.57$1.61$1.68$1.84$2.01$2.19$2.31$2.42$2.49n/a
Diluted shares, weightedn/an/a1,978m1,727m1,717m1,688m1,662m1,670m1,679m1,680m1,652m1,637m1,712m2,258m2,245m2,146m2,078m2,027m2,039m2,053m
Shares outstanding at period endn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a2,044m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008FY2009FY2010 †FY2011FY2012FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equityn/a12,24114,84315,71315,95613,62315,15414,85214,26616,17711,74114,03151,59837,82235,94631,06129,43016,33518,47323,404
Non-controlling interestn/a-33.0-58.0-75.0-89.015.082.013115817010696.010060.060.057.055.053.033.00.0
Short-term borrowingsn/a154231n/an/an/an/an/an/an/an/an/an/an/a4,948n/an/a2,046n/an/a
Debtn/a6,5856,1305,4455,4917,3948,3407,8326,6896,7087,9627,34946,73350,67644,36939,32039,77249,43145,11142,877
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/a0.06728338741,2611,5301,3701,8261,713
Other liabilitiesn/a10,5399,8629,99311,61214,86515,01610,93410,63510,65213,74213,51030,84129,09023,11725,12124,37223,36824,59520,778
Total liabilities and equityn/a29,48631,00831,07632,97035,89738,59233,74931,74833,70733,55134,986129,944118,481109,31496,82095,15992,60390,03888,772
Owned
Fixed assetsn/a5,4055,0554,6644,5215,3334,5794,4174,4124,9805,0015,0276,2525,8866,0496,2556,6467,1367,5437,971
Goodwilln/a4,8275,2185,2335,5867,6357,0967,0276,8816,8756,8636,53822,48820,54720,50221,14921,16921,71921,75421,735
Intangible assets1,3301,1512,8653,3703,1248,7782,3181,7531,4191,3851,2101,09163,96953,24342,52735,85927,07223,30719,10316,936
Investmentsn/a4772,2004,9495,8664,6964,6866,2726,5454,8323,8713,6233,8141,7182,9871301,1808338603,385
Cash and equivalents1,8017,9767,6835,0335,7761,6563,5865,5712,3854,2375,4216,91112,34614,54613,9799,12311,46410,34610,2099,574
Receivablesn/a3,6441,8971,9852,2501,7081,6902,1002,9483,7744,3474,6366,4767,2197,9798,1518,8829,0129,5929,192
Inventoryn/a1,7651,4131,2041,3841,6571,4981,5601,2211,2411,1661,1954,2932,0742,0952,3392,6622,5572,6902,704
Other assetsn/a4,2414,6774,6384,4634,43413,1395,0495,9376,3835,6725,96510,30613,24813,19613,81416,08417,69318,28717,275
Total assetsn/a29,48631,00831,07632,97035,89738,59233,74931,74833,70733,55134,986129,944118,481109,31496,82095,15992,60390,03888,772
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded11.3%2.5%1.4%4.2%
Profit growth, compounded16.2%n/a3.7%53.1%
Return on equity, average10.5%10.1%3.6%38.2%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Bristol-Myers Squibb's revenue in fiscal 2025?

Bristol-Myers Squibb (BMY) reported revenue of $48.2 billion for fiscal 2025, the year ended 31 December 2025, down 0.2% on the year before.

How much did Bristol-Myers Squibb earn in fiscal 2025?

Net income was $7.1 billion for fiscal 2025, and diluted earnings per share $3.46.

What is Bristol-Myers Squibb's P/E ratio?

At the close of 6 November 2026, Bristol-Myers Squibb traded at 13.8 times its earnings over the twelve months to 30 September 2026.

What is Bristol-Myers Squibb's market cap?

The market cap of Bristol-Myers Squibb was $127.0 billion at the close of 6 November 2026.

Does Bristol-Myers Squibb pay a dividend?

Yes. Bristol-Myers Squibb declared $2.52 a share in dividends over the four quarters to 30 September 2026.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
All 175 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
GSK plc GSK *$101.0 billion13.5334.9%24.3%4.1%1.083.4%
Regeneron Pharmaceuticals, Inc. REGN$95.5 billion19.9714.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.4 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$53.3 billion45.5863.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.7 billion99.096.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$37.5 billion44.276.9%57.1%11.4%0.881.4%
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.5 billion34.8916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$32.4 billion13.5175.3%n/a1.0%2.742.6%
Roivant Sciences Ltd. ROIV$28.1 billionn/a-6.3%-7,914.8%-67.6%0.00n/a
Insmed Inc. INSM$25.1 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$23.8 billion21.2119.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$22.8 billionn/a-4.4%-0.0%4.3%0.972.4%
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.9 billion8.1075.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.1 billion79.824.9%9.0%13.5%1.33n/a
Kiniksa Pharmaceuticals International, plc KNSA$14.7 billion72.1615.4%13.8%58.2%0.00n/a
BridgeBio Pharma, Inc. BBIO$14.6 billionn/an/a-38.5%167.3%n/an/a
Elanco Animal Health Inc. ELAN$12.9 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.5111.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Biomarin Pharmaceutical Inc. BMRN$10.8 billionn/a-0.3%3.1%18.1%0.67n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
Madrigal Pharmaceuticals, Inc. MDGL$9.3 billionn/a-24.8%-10.7%92.8%0.54n/a
TG Therapeutics, Inc. TGTX$9.2 billion21.8273.1%17.1%76.1%1.23n/a
ImmunityBio, Inc. IBRX$9.1 billionn/an/a-151.9%192.9%n/an/a
Krystal Biotech, Inc. KRYS$8.9 billion40.8215.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.6 billion27.9731.5%58.6%163.7%0.00n/a
Arrowhead Pharmaceuticals, Inc. ARWR$8.2 billionn/a-68.7%-33.8%16.8%1.86n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.2419.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.8 billionn/a-220.3%-66.7%61.0%1.17n/a
Alkermes plc. ALKS$7.7 billionn/a-0.0%3.7%15.3%0.81n/a
Twist Bioscience Corp. TWST$7.6 billionn/a-30.7%-33.6%19.2%0.03n/a
Cytokinetics Inc. CYTK$7.5 billionn/an/a-625.2%29.9%n/an/a
Axsome Therapeutics, Inc. AXSM$7.0 billionn/a-149.2%-17.5%54.2%1.78n/a
CG Oncology, Inc. CGON$6.8 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Lantheus Holdings, Inc. LNTH$6.6 billion24.7819.9%18.6%2.4%0.42n/a
Ionis Pharmaceuticals Inc. IONS$6.5 billionn/a-128.5%-68.0%-7.4%3.01n/a
Amneal Pharmaceuticals, Inc. AMRX$6.4 billion41.10476.5%14.6%9.3%80.86n/a
Ligand Pharmaceuticals Inc. LGND$6.1 billion136.655.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.1 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.7 billionn/an/an/an/a0.77n/a
PTC Therapeutics, Inc. PTCT$5.5 billionn/an/a12.8%-35.1%n/an/a
Crispr Therapeutics AG CRSP$4.9 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Gossamer Bio, Inc. GOSS$4.8 billionn/an/a-311.7%32.4%n/an/a
Travere Therapeutics, Inc. TVTX$4.7 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.5 billionn/a-40.0%-16.2%17.9%1.90n/a
Relay Therapeutics, Inc. RLAY$4.1 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Liquidia Corp. LQDA$4.0 billion32.3971.0%37.4%2,233.6%n/an/a
Xenon Pharmaceuticals Inc. XENE$3.8 billionn/a-32.9%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.7 billion10.0626.1%10.2%14.8%0.00n/a
AbCellera Biologics Inc. ABCL$3.6 billionn/a-18.4%-340.2%101.3%0.00n/a
Organon & Co. OGN$3.6 billion18.2217.9%n/a-3.2%7.170.6%
Tango Therapeutics, Inc. TNGX$3.6 billionn/a-12.1%-253.4%121.5%0.00n/a
Viking Therapeutics, Inc. VKTX$3.4 billionn/a-106.6%n/an/a0.43n/a
Tarsus Pharmaceuticals, Inc. TARS$3.4 billionn/a-675.0%-102.0%86.3%0.700.0%
Supernus, Inc. INDV$3.3 billion7.88n/a40.6%16.4%n/an/a
DBV Technologies S.A. DBVT$3.3 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.2 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.2 billion121.6412.3%6.9%60.0%0.45n/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Supernus, Inc. SUPN$3.1 billion9.62n/a45.5%16.2%n/an/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.0 billionn/an/an/an/a0.00n/a
Adma Biologics, Inc. ADMA$2.8 billion16.5241.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Vericel Corp. VCEL$2.8 billion85.298.7%8.3%25.3%0.00n/a
Xeris Biopharma Holdings, Inc. XERS$2.8 billionn/a-13.3%12.7%38.4%3.89n/a
Beam Therapeutics Inc. BEAM$2.7 billionn/a-11.2%-267.7%163.3%0.11n/a
Xencor Inc. XNCR$2.7 billionn/a-21.0%-72.7%33.5%0.17n/a
Neogen Corp. NEOG$2.6 billionn/a-2.7%-0.8%-0.3%0.37n/a
Celldex Therapeutics, Inc. CLDX$2.3 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.3 billionn/a-126.5%-475.0%-58.3%0.28n/a
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Schrodinger, Inc. SDGR$2.2 billionn/a-19.6%-49.6%4.8%0.00n/a
Septerna, Inc. SEPN$2.2 billionn/a-6.3%-44.0%13,520.1%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1947.8%48.6%21.0%0.00n/a
Perrigo Co. plc PRGO$2.2 billionn/a-72.5%-39.4%-4.5%1.357.3%
Immunome Inc. IMNM$2.1 billionn/a-48.4%n/an/a0.00n/a
Zymeworks Inc. ZYME$2.1 billionn/a-186.6%-419.0%-69.8%0.00n/a
Vir Biotechnology, Inc. VIR$2.1 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.0 billion13.268.0%25.0%5.1%1.07n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Trulieve Cannabis Corp. TRLV$2.0 billionn/a-57.8%-25.6%-9.1%0.37n/a
Biocryst Pharmaceuticals Inc. BCRX$2.0 billionn/an/a-30.1%60.3%n/an/a
Harmony Biosciences Holdings, Inc. HRMY$1.9 billion10.9616.7%22.2%19.8%0.14n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Sarepta Therapeutics, Inc. SRPT$1.9 billionn/a-7.5%-2.5%-18.9%0.56n/a
Maze Therapeutics, Inc. MAZE$1.9 billionn/an/an/an/a0.09n/a
Novavax Inc. NVAX$1.8 billionn/an/a-21.2%-61.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.8 billionn/a-38.1%-297.7%214.4%0.00n/a
Stoke Therapeutics, Inc. STOK$1.7 billionn/a-69.0%-913.1%-86.3%0.00n/a
Generate Biomedicines, Inc. GENB$1.7 billionn/an/an/an/a0.00n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.6130.5%41.3%738.8%0.000.0%
Eton Pharmaceuticals, Inc. ETON$1.6 billion37.1357.4%28.8%100.6%0.27n/a
Immunocore Holdings plc IMCR$1.6 billionn/a-7.7%-6.8%13.1%0.940.0%
Precigen, Inc. PGEN$1.6 billion128.0629.1%21.4%n/a1.12n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
uniQure N.V. QURE$1.5 billionn/a-79.0%-1,001.7%28.0%0.17n/a
ANI Pharmaceuticals Inc. ANIP$1.5 billion13.2818.3%16.0%25.9%0.95n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.175.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.4 billionn/a-58.0%-603.0%-8.1%0.14n/a
Nuvation Bio Inc. NUVB$1.4 billionn/a-59.6%-61.2%654.2%1.25n/a
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Innoviva, Inc. INVA$1.4 billion9.6017.0%38.8%12.8%0.23n/a
Phibro Animal Health Corp. PAHC$1.3 billion13.1824.6%12.5%10.1%1.761.5%
Cronos Group Inc. CRON$1.3 billion21.295.4%3.4%55.8%0.00n/a
Avalyn Pharma Inc. AVLN$1.3 billionn/an/an/an/a0.04n/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Mannkind Corp. MNKD$1.3 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.2 billionn/an/an/an/an/an/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.0112.1%18.7%3.1%0.75n/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Janux Therapeutics, Inc. JANX$1.1 billionn/a-11.0%-599.3%132.9%0.00n/a
Harrow, Inc. HROW$1.0 billionn/a-244.9%-1.0%21.1%19.24n/a
Cryoport, Inc. CYRX$969 millionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$921 millionn/an/an/an/a0.00n/a
Monte Rosa Therapeutics, Inc. GLUE$901 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$857 millionn/an/a-61.7%159.5%n/an/a
MeiraGTx Holdings plc MGTX$847 million12.6636.6%46.3%948.3%0.46n/a
Aktis Oncology, Inc. AKTS$847 millionn/an/an/an/a0.00n/a
Verastem, Inc. VSTM$794 millionn/an/an/an/a11.82n/a
Lexicon Pharmaceuticals, Inc. LXRX$791 millionn/a-38.1%-147.4%-45.6%0.32n/a
Nektar Therapeutics NKTR$759 millionn/a-17.4%-257.8%-27.2%0.00n/a
Collegium Pharmaceutical, Inc. COLL$752 million24.2012.9%15.2%7.7%3.65n/a
Rigel Pharmaceuticals Inc. RIGL$746 million2.5569.0%26.3%2.2%0.02n/a
QuidelOrtho Corp. QDEL$732 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ironwood Pharmaceuticals Inc. IRWD$728 million4.89n/a62.9%18.1%n/an/a
Ardelyx, Inc. ARDX$722 millionn/a-33.8%-7.7%17.6%1.54n/a
Arbutus Biopharma Corp. ABUS$721 million4.6259.2%82.0%1,078.8%0.00n/a
Ginkgo Bioworks Holdings, Inc. DNA$718 millionn/a-69.2%-259.9%-51.5%0.00n/a
Zevra Therapeutics, Inc. ZVRA$690 million9.6032.7%60.8%75.1%0.00n/a
Wave Life Sciences, Inc. WVE$665 millionn/a-52.4%-320.9%n/a0.00n/a
Design Therapeutics, Inc. DSGN$651 millionn/a-36.6%n/an/a0.00n/a
Kura Oncology, Inc. KURA$645 millionn/a-612.8%-411.9%n/a0.20n/a
Geron Corp. GERN$636 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$588 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$565 millionn/a-48.0%-14.3%-2.6%0.45n/a
Gyre Therapeutics, Inc. GYRE$510 millionn/a-37.5%-20.6%13.5%0.00n/a
Monopar Therapeutics MNPR$479 millionn/an/an/an/a0.00n/a
CytomX Therapeutics, Inc. CTMX$476 millionn/a-30.0%-676.5%-87.7%0.00n/a
Aquestive Therapeutics, Inc. AQST$454 millionn/an/a-114.1%12.5%n/an/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$425 millionn/an/a-9.3%86.8%n/an/a
Puma Biotechnology, Inc. PBYI$421 million15.8519.3%13.2%-2.9%0.00n/a
Arvinas, Inc. ARVN$419 millionn/a-1.8%-12.1%-11.8%0.00n/a
CorMedix Inc. CRMD$412 million2.4840.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$374 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$276 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$143 millionn/an/an/an/an/an/a
125 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on BMY

Dividends$2.52 a share over the four quarters to 30 September 2026, a 4.06% yield
Filings20 in twelve months: 8 current reports (8-K), about 5 regulation FD disclosure; 4 results of operations; 2 other events; 1 shareholder vote
Planned insider sales4 Form 144 notices in twelve months, $2.5 million; latest 6 November 2026
Options tapeput/call 1.2 by open interest at the 6 November 2026 close; the straddle prices a 3.9% move to 13 November 2026
13F holders2,541 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading5 sales and 0 purchases on Form 4 in twelve months
Congress1 House trade disclosed in six months
Short interest49.9 million shares short, 3.65 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 202629 October 2026EDGAR
10-Q30 June 202630 July 2026EDGAR
10-Q31 March 202630 April 2026EDGAR
10-K31 December 202511 February 2026EDGAR
10-Q30 September 202530 October 2025EDGAR
10-Q30 June 202531 July 2025EDGAR
10-Q31 March 202524 April 2025EDGAR
10-K31 December 202412 February 2025EDGAR
10-Q30 September 202431 October 2024EDGAR
10-Q30 June 202426 July 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.